Mark Bloch

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

Andrew E. Grulich, Rebecca Guy, Janaki Amin et al. · The Lancet HIV · 2018 · 362 citations · Full text

Sexual Health, Preventive Medicine, Epidemiological Outcome +9

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Naomi Schlesinger, Rieke Alten, Thomas Bardin et al. · Annals of the Rheumatic Diseases · 2012 · 338 citations

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Open-label Trial, Hepatology, Hepatitis C +12

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

Frank van Leth, Prahpan Phanuphak, Erik S.G. Stroes et al. · PLoS Medicine · 2004 · 274 citations · Full text

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

Allison Martin, Mark Bloch, Janaki Amin et al. · Clinical Infectious Diseases · 2009 · 222 citations · Full text